We first assessed the activity of selective Bcl-2 family protein inhibitors as single agents in LNCaP95, VCaP-CR, and 22Rv1 prostate cancer cell lines (Supplementary Fig. S2; Supplementary Table S1). This evidence concerns the gene BCL2 and prostate cancer.